v3.23.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Operating activities:    
Net loss $ (188,602,000) $ (93,919,000)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization expense 10,112,000 6,855,000
Goodwill impairment 77,280,000 0
Amortization of financing lease right-of-use asset 153,000 168,000
Amortization (accretion) of interest on securities (309,000) 695,000
Non-cash lease expense 38,000 383,000
Net realized loss (gain) on investments 23,000 0
Stock-based compensation 11,806,000 16,938,000
Change in fair value of contingent consideration 2,528,000 237,000
Cost of leased equipment sold to customer 88,000 204,000
Changes in operating assets and liabilities:    
Accounts receivable (1,646,000) (1,134,000)
Inventory (3,819,000) (18,121,000)
Prepaid expenses and other current assets 1,376,000 (3,387,000)
Other assets (7,798,000) (52,000)
Accounts payable 2,401,000 (1,233,000)
Accrued expenses and contract liabilities 967,000 2,067,000
Net cash used in operating activities (95,402,000) (90,299,000)
Investing Activities:    
BioDiscovery acquisition, return of purchase consideration from escrow 0 694,000
Purigen acquisition, return of purchase consideration from escrow 96,000 0
Purchases of property and equipment (946,000) (1,055,000)
Purchase of available for sale securities (4,485,000) (63,208,000)
Sale and maturity of available for sale securities 84,866,000 135,386,000
Construction in progress 0 (686,000)
Sale of property and equipment 0 26,000
Net cash provided by investing activities 79,531,000 71,157,000
Financing activities:    
Principal payments on financing lease liability (34,000) (26,000)
Proceeds from sale of common stock 46,411,000 23,128,000
Offering expenses on sale of common stock (1,161,000) (578,000)
Proceeds from sale of common stock under employee stock purchase plan 92,000 75,000
Proceeds from warrant and option exercises 23,000 262,000
Net cash provided by financing activities 45,331,000 22,861,000
Effect of exchange rates on cash, cash equivalents and restricted cash 17,000 (124,000)
Net decrease in cash, cash equivalents and restricted cash 29,477,000 3,595,000
Cash, cash equivalents and restricted cash at beginning of period 5,491,000 24,571,000
Cash, cash equivalents and restricted cash at end of period 34,968,000 28,166,000
Reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets to the total amounts reported on the unaudited condensed consolidated statements of cash flows    
Cash and cash equivalents 34,568,000 28,166,000
Restricted cash 400,000 0
Total cash, cash equivalents and restricted cash at end of period 34,968,000 28,166,000
Supplemental cash flow disclosures:    
Cash paid for interest 221,000 222,000
Cash paid for operating lease liabilities 1,938,000 1,166,000
Supplemental disclosure of non-cash investing and financing activities:    
Transfer of instruments and servers from inventory to property and equipment, net 7,112,000 5,500,000
Property and equipment included in accounts payable 434,000 857,000
Construction in progress included in accounts payable 0 106,000
Operating lease liabilities resulting from obtaining right-of-use assets $ 0 $ 517,000